Improving the control of energy homeostasis can lower cardiovascular risk in metabolically compromised individuals. To identify new regulators of whole-body energy control, we conducted a high-throughput screen in transgenic reporter zebrafish for small molecules that modulate the expression of the fasting-inducible gluconeogenic gene pck1. We show that this in vivo strategy identified several drugs that impact gluconeogenesis in humans, as well as metabolically uncharacterized compounds. Most notably, we find that the Translocator Protein (TSPO) ligands PK 11195 and Ro5-4864 are glucose lowering agents despite a strong inductive effect on pck1 expression. We show that these drugs are activators of a fasting-like energy state, and importantly that they protect high-fat diet induced obese mice from hepatosteatosis and glucose intolerance, two pathological manifestations of metabolic dysregulation. Thus, using a whole-organism screening strategy, this study has identified new small molecule activators of fasting metabolism.
Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism
P. Gut,B. Baeza-Raja,Olov Andersson,Laura-Carolin Hasenkamp,J. Hsiao,D. Hesselson,K. Akassoglou,E. Verdin,M. Hirschey,D. Stainier
Published 2012 in Nature Chemical Biology
ABSTRACT
PUBLICATION RECORD
- Publication year
2012
- Venue
Nature Chemical Biology
- Publication date
2012-11-13
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-55 of 55 references · Page 1 of 1